ABOUT ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Phase C, members will obtain ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment until finally sickness progression or perhaps the contributors are not able to tolerate the study drugs.There may be greater treatment stress for individuals in this trial as compared to